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Altered metabolism represents one of the oldest hallmarks
associated with cancer. The aberrant metabolic profile deals
primarily with the well-known switch of transformed cells
towards aerobic glycolysis from mitochondrial oxidative
phosphorylation. In addition, it deals with the exacerba-
tion of several biosynthetic pathways interconnected with
the increased glycolytic flux, eventually conferring selective
metabolic advantages.
The distinctive and ubiquitous nature of this altered
metabolic profile expressed by cancer cells from various
origins or tissues turns the modulation/reversion of these
aberrations as an amenable strategy for new anticancer
therapies. Despite Otto Warburg’s pioneering observations,
targeting cancer cell metabolism for therapeutic purposes
still remains theoretical. Several factors have contributed to
this situation. Primarily, for many years, cancer has been
treated as a homogeneous and too simplistic cellular system,
where the impairment of proliferation/viability of the most
abundant differentiated cancer cells has been extensively
pursued. This approach, however, has not been successful
in preventing tumour relapse. Cancer is nowadays consid-
ered a complex network, including cancer cells at different
stages of differentiation, as well as noncancer cells from
the tumour microenvironment. These cells exert specific
functions further sustaining cancer progression, bymaintain-
ing a proinflammatory environment, by inducing activation
of angiogenesis and by evading immune responses. The
cellular heterogeneity implies more subtle forms of mutual
interaction and communication among different cells and
with the microenvironment, which may be the niche for
future innovative anticancer therapeutic interventions.
In this renewed view of cancer etiology, unexpected
crosstalk is emerging betweenmetabolicmediators/processes
and pathological alterations.
This special issue focuses on “Metabolism and cancer:
old and new players” and intends to stimulate the discus-
sion about new emerging targetable mediators of cancer
metabolism and to evaluate possible noncanonical roles of
old players in tumorigenesis as well as in cancer metabolism.
The impairment of cancer cell viability by induction of
cell death remains the final outcome of many anticancer
strategies. Besides apoptosis, other modes of cell death
have been defined and are attracting interest as alternative
therapeutically exploitable approaches to impact apoptosis-
resistant forms of cancer.The review by S. Fulda, “Alternative
cell death pathways and cell metabolism,” draws attention to
the programmed form of necrosis, namely, necroptosis, and
discusses the relevance of metabolic pathways involved in its
modulation. The author suggests a possible interconnection
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between alterations of redox signaling pathways mediating
necroptosis and mitochondrial impairment, which implies
the latter as a crucial regulator of redox imbalance.
An ideal anticancer therapy should be able to efficiently
target cancer stem cells. This requires the discovery of
markers selectively identifying malignant stem cells. The
review by C. Pecqueur et al., “Targeting metabolism to induce
cell death in cancer cells and cancer stem cells,” addresses
the relationship between cancer cell metabolism and evasion
from apoptosis by comparing the main features of cancer
cells and cancer stem cells. The authors correlate the peculiar
metabolic characteristics of these two types of cancer cells
with their ability to evade apoptosis.
Over the last 10 years, noncanonical roles for many
factors implicated in apoptosis were published. The family
of B-cell lymphoma-2 (Bcl-2) proteins represents one of the
most interesting examples, with several members exhibiting
essentially pro- and apoptotic functions. The paper by J.
Michels et al., “Functions of Bcl-xL at the interface between cell
death andmetabolism,” reviews new and intriguing properties
of the Bcl-2 homolog Bcl-xL (B-cell lymphoma extra-large)
linked to regulation of bioenergetic metabolism, which in
turn controls important processes including mitochondrial
ATP synthesis, Ca2+ flux, autophagy, mitosis, and protein
acetylation.
Cancer cells rely on glycolysis rather than on oxidative
phosphorylation to fulfill their energy needs. In conditions
of glucose deprivation, however, cancer cells may reactivate
mitochondrial bioenergetics as part of a prosurvival strategy.
The study by R. Palorini et al., “Mitochondrial complex
I inhibitors and forced oxidative phosphorylation synergize
in inducing cancer cell death,” shows that mitochondrial
complex I inhibitors sensitize cancer cells to cell death
under glucose depletion. Interestingly, combined treatments
affecting glycolysis and leading to mitochondria impairment
are ineffective on immortalized cells or cancer cells cultivated
under high glucose conditions. Their results suggest that the
forced switch from glycolysis to oxidative phosphorylation
combined with the use of mitochondrial inhibitors may
be used as alternative therapeutic approach to increase the
sensitivity of cancer cells to death.
Identification of specific metabolic intermediates as tar-
gets for future anticancer treatments may be at the basis
for attempting a reversal of tumor metabolism to normal
conditions, with the rationale of impairing cancer growth.
Pyruvate kinaseM2 (PKM2) catalyzing the final rate-limiting
reaction of glycolysis currently attractsmuch interest because
of its multiple emerging intracellular functions. The review
by N. Wong et al., “PKM2, a central point of regulation
in cancer metabolism,” gives an overview of our current
knowledge about this important enzyme, discussing several
of its potential contributions to tumorigenesis.
A limiting factor in exploiting cancer metabolism for
therapeutic purposes is the lack of availability of agents
acting as specific modulators of cancer metabolism. The
review by C. Cerella et al., “Natural compounds as regulators
of the cancer cell metabolism,” covers this aspect, focusing
on natural compounds as untapped potential regulators of
cancer cell metabolism.The authors discuss some of themost
important pathways and factors implicated in altered cancer
metabolism and give an overview of compounds extracted
from natural sources potentially targeting these different
aberrantly regulated metabolic key intermediates.
The link between obesity, insulin resistance, and cancer
is explored from different sides in three papers of this
special issue, interestingly dealing all with hormonal forms
of cancer.The paper by C. Brosseau et al., “Role of insulin-like
growth factor binding protein-3 in 1, 25-dihydroxyvitamin-D
3
-
induced breast cancer cell apoptosis,” aims at identifying the
mechanisms involved in 1, 25-dihydroxyvitamin D
3
-induced
apoptosis in breast cancer cells. Their strategy suggests a role
for insulin-like growth factor binding protein-3 (IGFBP-3) in
vitamin D-induced apoptotic signaling and the involvement
of impaired secretion of IGFBP-3 in acquired chemoresis-
tance.
The review by J. S. Byun and K. Gardner, “C-terminal
binding protein: a molecular link betweenmetabolic imbalance
and epigenetic regulation in breast cancer,” introduces the
reader to the concept of metabolic transduction by stressing
the link between shifts in carbohydrate metabolism and
alterations in epigenetic regulatory mechanisms. In partic-
ular, these authors investigate the family of transcriptional
repressors calledC-terminal binding proteins (CtBPs), whose
function is controlled by NAD+ levels, as an example of
factors interacting and modulating the activity of different
histone deacetylases (HDACs) depending on the metabolic
status.
Finally, the review by J. H. Gunter et al., “New play-
ers for advanced prostate cancer and the rationalisation of
insulin-sensitising medication,” points to the roles played by
metabolic disorders (especially related to insulin resistance)
in favoring anticancer treatment failure and consequent
higher cancer-specific mortality. The authors discuss the
promising use of insulin-sensitizing drugs as potential anti-
cancer agents to be used in combinational therapies.
Although alterations in cellular metabolism are an old
acquaintance in cancer etiology, we still need to do more
before we can translate our knowledge into new and specific
anticancer therapies. This final outcome will mostly depend
on an in-depth identification of the mutual modulation
between metabolism processes and factors that regulate
proliferation and death/survival of cancer cells. With this
special issue, we hope to offer new and relevant insights
towards a critical reevaluation of this rapidly moving field.
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